How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) posted its earnings results on Tuesday, November, 9th. The financial services provider reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.09.

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA) , AbbVie (ABBV) , Adaptimmune Therapeutics (ADAP) , Alector (ALEC) , Dynavax Technologies (DVAX) , Homology Medicines (FIXX) , Gilead Sciences (GILD) , Novan (NOVN) , Pfizer (PFE) and Akebia Therapeutics (AKBA) .

When did Satsuma Pharmaceuticals IPO?

Satsuma Pharmaceuticals (STSA) raised $75 million in an initial public offering on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

NASDAQ:STSA

Satsuma Pharmaceuticals (STSA) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free STSA Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.01
▼
$1.14
50-Day Range: $1.04
▼
$1.11
52-Week Range: $0.59
▼
$8.08

Volume: 1.83 million shs
Average Volume: 701,788 shs
Market Capitalization: $36.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Satsuma Pharmaceuticals alerts:

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Satsuma Pharmaceuticals Stock (NASDAQ:STSA)

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

STSA Stock News Headlines

August 30, 2023 | usnews.com

Satsuma City High School

June 9, 2023 | bizjournals.com

Japanese pharma acquires its crash-strapped Durham spin-out

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

June 8, 2023 | bizjournals.com

Japanese pharma acquires its Durham spin-out

May 18, 2023 | finance.yahoo.com

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

May 3, 2023 | marketwatch.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRA

May 1, 2023 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nippon

April 25, 2023 | marketwatch.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRA

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 22, 2023 | seekingalpha.com

STSA Satsuma Pharmaceuticals, Inc.

April 21, 2023 | finance.yahoo.com

Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting

April 19, 2023 | msn.com

After Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More Upside

April 18, 2023 | marketwatch.com

Satsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSA

April 17, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. Buyout

April 17, 2023 | bizjournals.com

Peninsula company bets big part of potential $221M sale on future of migraine drug

April 17, 2023 | markets.businessinsider.com

Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical

April 17, 2023 | msn.com

Satsuma Skyrockets after Acquisition by Shin Nippon

April 17, 2023 | investorplace.com

Why Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?

April 16, 2023 | finance.yahoo.com

SNBL to Acquire Satsuma Pharmaceuticals

March 30, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)

March 30, 2023 | finance.yahoo.com

We're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Rate

March 29, 2023 | bizjournals.com

Migraine drug maker seeks FDA approval and a partner as it cuts jobs

March 28, 2023 | finance.yahoo.com

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

February 18, 2023 | marketwatch.com

8-K: Satsuma Pharmaceuticals, Inc.

February 7, 2023 | reuters.com

STSA.O

February 2, 2023 | finance.yahoo.com

Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference

December 28, 2022 | finance.yahoo.com

Despite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For Approval

See More Headlines

Receive STSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Regional Banks
Current Symbol: NASDAQ:STSA
CUSIP: 85931930
CIK: 891106
Web: www.satsumarx.com
Phone: 650-410-3200
Fax: N/A
Employees: 21
Year Founded: 2016

Profitability

EPS (Most Recent Fiscal Year): ($2.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-70,060,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -115.24%
Return on Assets: -102.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.44
Quick Ratio: 7.44

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.41 per share
Price / Book: 0.78

Miscellaneous

Outstanding Shares: 33,150,000
Free Float: 22,809,000
Market Cap: $36.47 million
Optionable: Not Optionable
Beta: 0.10

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. John A. Kollins MBA (Age 59)
Pres, CEO & Director
Comp: $830k
Mr. Thomas P. O'Neil (Age 57)
Chief Financial Officer
Comp: $550.08k
Dr. Detlef F. Albrecht (Age 61)
Chief Medical Officer
Comp: $625.97k
Mr. Mic Iwashima (Age 44)
VP & Head of Operations
Mr. Robert Schultz (Age 58)
Sr. VP & Head of Chemistry, Manufacturing and Controls
Dr. Shannon Strom Ph.D. (Age 46)
VP & Head of Regulatory Affairs
Mr. Robert M. Janosky
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders

Ken Takanashi
Bought 22,053,581 shares on 6/6/2023
Total: $20.07 M ($0.91/share)

STSA Stock Analysis - Frequently Asked Questions

How were Satsuma Pharmaceuticals' earnings last quarter?: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) posted its earnings results on Tuesday, November, 9th. The financial services provider reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.09.
What other stocks do shareholders of Satsuma Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).
When did Satsuma Pharmaceuticals IPO?: Satsuma Pharmaceuticals (STSA) raised $75 million in an initial public offering on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO.

This page (NASDAQ:STSA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Satsuma Pharmaceuticals (STSA) Stock Price, News & Analysis

About Satsuma Pharmaceuticals Stock (NASDAQ:STSA)

STSA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders

STSA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info